Seven Bridges Genomics Inc.

Seven Bridges Genomics Inc., a foreign-owned for-profit corporation headquartered in Charlestown, Massachusetts, delivers cloud-based genomic data management, analysis platforms, and bioinformatics services to federal research agencies as a sub-recipient on grant programs (67% of recent awards) and as a prime on federal service contracts and purchase orders (33%). The vendor operates predominantly under non-set-aside competitive procurements across the National Institutes of Health portfolio.

The company's federal footprint concentrates heavily within the Department of Health and Human Services, specifically the National Institutes of Health. Top customers by award count cover 87% of recent awards: NIH Office of the Director (4 awards), NIH National Cancer Institute (3 awards, $11.6 million combined potential value), and NIH National Institute on Aging (3 awards). The National Cancer Institute anchors the potential-value ranking at $11.6 million, followed by the National Institute on Drug Abuse ($750 thousand) and a smaller Office of Logistics and Acquisition Operations purchase order ($152 thousand). All identified customer agencies operate within HHS, signaling concentrated market presence in federal biomedical research rather than distributed civilian or defense agency exposure.

Seven Bridges' concrete capability portfolio centers on CAVATICA, a cloud-based platform for multi-omic data analysis, storage, and sharing. Prime contract work includes a $749.650 thousand National Institute on Drug Abuse purchase order (awarded May 1, 2023, completion October 31, 2025) for Single Sign On integration within CAVATICA and Tier 1 licensing with options through 2025; and a $152.322 thousand HHS Office of Logistics and Acquisition Operations purchase order (awarded August 31, 2026, completion August 30, 2027) for CAVATICA software renewal. As a grant sub-recipient, Seven Bridges operates under Children's Hospital of Philadelphia, Jackson Laboratory, Sage Bionetworks, and Icahn School of Medicine at Mount Sinai as prime grantees on NIH-funded data coordinating center and genomic research programs. Representative sub-recipient work includes the INCLUDE Down Syndrome Data Coordinating Center (awarded March 23, 2026), where Seven Bridges provides platform infrastructure, data ecosystem engineering, and bioinformatics tool development; the Kids First Data Resource Center (multiple awards through October 2024 and December 2025), where the vendor enhances CAVATICA integration and data-sharing capability; and PDXNet Portal support under Jackson Laboratory (awarded February 28, 2024 and November 29, 2024) to maintain the patient-derived xenograft research portal, Cancer Genomics Cloud infrastructure, and workflow standardization.

Activity shows growth from two awards in 2023 to seven in 2024, then declining to one in 2025 and two in 2026—a trajectory reflecting the lumpy timing of multi-year grant renewals and research program cycles rather than sustained quarter-to-quarter contracting. Only one award ($152 thousand) faces recompete within the next twenty-four months. SCI-reported invoiced revenue on prime service contracts totals $256 thousand across FY2023–FY2025, with $137 thousand invoiced in FY2024 across 0.2 FTEs and $120 thousand in FY2025 across 0.0 FTEs; the SCI dataset reflects only service contracts above the $150,000 reporting threshold and excludes grants, software licensing, and other transaction types that dominate Seven Bridges' actual federal revenue. Government-paid hourly rates on SCI-reportable prime contracts derive consistently at $345.17 per hour. Across SCI prime contracts, Seven Bridges reports zero sub-hours share, indicating direct delivery without internal subcontractor leverage on federal service engagements. The vendor's sub-recipient footprint on NIH grants, however, positions it within larger research consortia where it manages technical delivery to prime grantees rather than holding direct agency relationships.